Nebulized liposomal amikacin for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis patients

Expert Opinion on Investigational Drugs

Volumn 23, Issue 5, 2014, Pages 743-749

  Ehsan, Zarmina ^a   Wetzel, Jacqueline Denise ^a   Clancy, John P ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Amikacin; Cystic fibrosis; Liposomes; Pseudomonas aeruginosa

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ARIKACE; AZTREONAM; AZTREONAM LYSINE; COLISTIMETHATE; FOSFOMYCIN; LEVOFLOXACIN; LIPOSOMAL AMIKACIN; PODHALER; TOBRAMYCIN; UNCLASSIFIED DRUG; AMIKACIN; LIPOSOME;

ARTICLE; CYSTIC FIBROSIS; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STRUCTURE; HUMAN; LUNG INFECTION; NEBULIZATION; PHASE 3 CLINICAL TRIAL (TOPIC); PSEUDOMONAS INFECTION; ANIMAL; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; NEBULIZER; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; AMIKACIN; ANIMALS; CYSTIC FIBROSIS; HUMANS; LIPOSOMES; NEBULIZERS AND VAPORIZERS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TREATMENT OUTCOME;

EID: 84898417858     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.895322     Document Type: Article

References (44)

1. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science 1989;245(4922):1066-73
2. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005;352(19):1992-2001
3. Rogan MP, Stoltz DA, Hornick DB. Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutation-specific treatment. Chest 2011;139(6):1480-90
4. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: Genetic analysis. Science 1989;245(4922):1073-80
5. Hug MJ, Clarke LL, Gray MA. How to measure CFTR-dependent bicarbonate transport: From single channels to the intact epithelium. Methods Mol Biol 2011;741:489-509
6. Anderson MP, Gregory RJ, Thompson S, et al. Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science 1991;253(5016):202-5
7. Boucher RC. Airway surface dehydration in cystic fibrosis: Pathogenesis and therapy. Annu Rev Med 2007;58:157-70
8. Doring G, Flume P, Heijerman H, Elborn JS. Treatment of lung infection in patients with cystic fibrosis: Current and future strategies. J Cyst Fibros 2012;11(6):461-79
9. Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005;2;293(5):581-8
10. Zhao J, Schloss PD, Kalikin LM, et al. Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci USA 2012;109(15):5809-14
11. Oliver A, Canton R, Campo P, et al. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000;288(5469):1251-4
12. Kenna DT, Doherty CJ, Foweraker J, et al. Hypermutability in environmental pseudomonas aeruginosa and in populations causing pulmonary infection in individuals with cystic fibrosis. Microbiology 2007;153(Pt 6):1852-9
13. Ciofu O, Mandsberg LF, Wang H, Hoiby N. Phenotypes selected during chronic lung infection in cystic fibrosis patients: Implications for the treatment of pseudomonas aeruginosa biofilm infections. FEMS Immunol Med Microbiol 2012;65(2):215-25
14. Drenkard E, Ausubel FM. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 2002;416(6882):740-3
15. Lee TW, Brownlee KG, Conway SP, et al. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2003;2(1):29-34
16. Schaedel C, de Monestrol I, Hjelte L, et al. Predictors of deterioration of lung function in cystic fibrosis. Pediatr Pulmonol 2002;33(6):483-91
17. Meyer RD, Young LS, Armstrong D. Tobramycin (nebramycin factor 6): In vitro activity against Pseudomonas aeruginosa. Appl Microbiol 1971;22(6):1147-51
18. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;7;340(1):23-30
19. Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros 2011;10(1):54-61
20. Konstan MW, Geller DE, Minic P, et al. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial. Pediatr Pulmonol 2011;46(3):230-8
21. McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway pseudomonas aeruginosa in cystic fibrosis. Am J Resp Crit Care Med 2008;178(9):921-8
22. Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009;135(5):1223-32
23. Oermann CM, Retsch-Bogart GZ, Quittner AL, et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010;45(11):1121-34
24. Assael BM, Pressler T, Bilton D, et al. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A comparative efficacy trial. J Cyst Fibros 2012. [Epub ahead of print]
25. Yahav D, Farbman L, Leibovici L, Paul M. Colistin: New lessons on an old antibiotic. Clin Microbiol Infect 2012;18(1):18-29
26. Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis 2009;22(6):535-43
27. Schuster A, Haliburn C, Doring G, Goldman MH. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: A randomised study. Thorax 2013;68(4):344-50
28. Littlewood KJ, Higashi K, Jansen JP, et al. A network meta-Analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis. J Cyst Fibros 2012;11(5):419-26
29. Trapnell BC, McColley SA, Kissner DG, et al. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. Am J Resp Crit Care Med 2012;185(2):171-8
30. Kahan FM, Kahan JS, Cassidy PJ, Kropp H. The mechanism of action of fosfomycin (phosphonomycin). Ann NY Acad Sci 1974;235:364-86
31. Dasenbrook EC, Checkley W, Merlo CA, et al. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 2010;303(23):2386-92
32. Geller DE, Flume PA, Griffith DC, et al. Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob Agents Chemother 2011;55(6):2636-40
33. Geller DE, Flume PA, Staab D, et al. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with pseudomonas aeruginosa. Am J Resp Crit Care Med 2011;183(11):1510-16
34. Young DC, Zobell JT, Stockmann C, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. aminoglycosides. Pediatr Pulmonol 2013;48(11):1047-61
35. Okusanya OO, Bhavnani SM, Hammel J, et al. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob Agents Chemother 2009;53(9):3847-54
36. Coates AL, Green M, Leung K, et al. A comparison of amount and speed of deposition between the PARI LC STAR (R) jet nebulizer and an investigational eFlow(R) nebulizer. J Aerosol Med Pulm Drug Deliv 2011;24(3):157-63
37. Li Z, Zhang Y, Wurtz W, et al. Characterization of nebulized liposomal amikacin (arikace) as a function of droplet size. J Aerosol Med Pulm Drug Deliv 2008;21(3):245-54
38. Meers P, Neville M, Malinin V, et al. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic pseudomonas aeruginosa lung infections. J Antimicrob Chemother 2008;61(4):859-68
39. Weers J, Metzheiser B, Taylor G, et al. A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers. J Aerosol Med Pulm Drug Deliv 2009;22(2):131-8
40. Clancy JP. Clinical trials of lipidassociated aerosolized amikacin: The ArikaceTM story. Pediatr Pulm 2009;44(S32):186
41. Neville ME, Liu S, Artis C, et al. Functionality of foamy alveolar macrophages after inhalation of aerosolized liposomal amikacin (arikace-). Pediatr Pulm 2009;44(S32):356 Available from: Http://ClinicalTrials.Gov
42. Waters V, Ratjen F. Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. Cochrane DB Syst Rev 2012;12:CD010004
43. Clancy JP, Dupont L, Konstan MW, et al. Phase II studies of nebulised Arikace in CF patients with pseudomonas aeruginosa infection. Thorax 2013;68(9):818-25
44. Insmed Website. Available from: Http://www.insmed.com/images/usr/Insmed- AmikacinGraphic.jpg.